Judith A. Abraham

Cleveland Clinic — United States

Medicine · Health Sciences

47h-index12.9kcitations107works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(18), Proteoglycans and glycosaminoglycans research(14), Estrogen and related hormone effects(13), Monoclonal and Polyclonal Antibodies Research(13), Fibroblast Growth Factor Research(13)

Publications107 total

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05
Annals of Oncology·2025· 8 cited
Table S2 from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
2023Open Access
Supplementary Figure S2 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure S3 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Table 1 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure Legends from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure S4 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure S5 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure S4 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Figure Legends from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Data from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Data from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
2023Open Access
Supplementary Figure S1 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Data from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
2023Open Access
Supplementary Figure S2 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Supplementary Data from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
2023Open Access
Supplementary Methods from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Table S2 from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
2023Open Access
Supplementary Methods from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
Data from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Michael Klagsbrun(13), John C. Fiddes(12), Denis Gospodarowicz(8), Deborah Damm(7), Shigeki Higashiyama(6), Ayalew Mergia(5), Jeff Friedman(4), Kim Nasmyth(4), George F. Schreiner(4), Jeffrey N. Strathern(4), Amar J. S. Klar(4), Annette Tumolo(3), Lothar Schweigerer(3), Gera Neufeld(3), J.L. Whang(3), James Hicks(3), Moshe Marikovsky(3), R. Mitchell(2), Sanjoy Das(2), Sudhansu K. Dey(2)